Corbus Shares Plunge 31% on Adverse Events in Key Tumor Drug Study
CRBP sits 16% above its 52-week low of $6.72 on elevated volume (9.5× avg).
Summary
Corbus Pharmaceuticals shares plummeted 31% today following reports of adverse events in its Phase 1/2 clinical study for CRB-701, a lead oncology drug. The data revealed Grade 3 treatment-related adverse events in 19.2% of patients and life-threatening Grade 4 events in 0.9%. This negative market reaction comes despite earlier announcements today from the company and an 8-K filing that emphasized positive aspects of the same clinical data. The significant safety concerns, particularly the Grade 4 events, are weighing heavily on the stock and raise questions about the drug's future, even as the company maintains CRB-701 is safe and on track for a registrational study in summer 2026.
At the time of this announcement, CRBP was trading at $7.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $144.7M. The 52-week trading range was $6.72 to $20.56. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.